Daewoong Pharmaceutical Co., Ltd
KOSE:A069620 Voorraadrapport
Marktkapitalisatie: ₩1.6t
Daewoong Pharmaceutical Toekomstige groei
Future criteriumcontroles 1/6 Daewoong Pharmaceutical zal naar verwachting groeien in winst en omzet met respectievelijk 17.2% en 4.4% per jaar. De winst per aandeel zal naar verwachting groeien met 17% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12.3% zijn.
Belangrijke informatie
17.0%
Groei van de winst per aandeel
Pharmaceuticals winstgroei 37.6% Inkomstengroei 4.4% Toekomstig rendement op eigen vermogen 12.3% Dekking van analisten Good
Laatst bijgewerkt 01 Nov 2024
Recente toekomstige groei-updates
Price target increased by 7.8% to ₩190,000 Nov 02
Price target increased by 11% to ₩176,250 Oct 17
Consensus EPS estimates increase by 25% Jun 19
Price target decreased by 7.5% to ₩171,083 Aug 03
Price target decreased by 7.4% to ₩205,714 Feb 25
Consensus forecasts updated Jan 21
Toon alle updates
There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price Nov 06
Price target increased by 7.8% to ₩190,000 Nov 02
Price target increased by 11% to ₩176,250 Oct 17
Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly Oct 15
Investor sentiment improves as stock rises 15% Oct 11
Investor sentiment improves as stock rises 19% Aug 21
Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate Aug 13
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-In-Class PRS Inhibitor, Bersiporocin Jul 30
Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings Jul 24
Investor sentiment improves as stock rises 19% Jul 10
We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt Jul 04
Consensus EPS estimates increase by 25% Jun 19
High number of new and inexperienced directors May 03
New major risk - Revenue and earnings growth Mar 12
Upcoming dividend of ₩600 per share at 0.5% yield Dec 20
Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-Dose Administration of Nabota Nov 09
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy Nov 07
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema Sep 26
Price target decreased by 7.5% to ₩171,083 Aug 03
Daewoong Pharmaceutical Obtains Approval for SGLT2i + Metformin Combination Drug Envlomet Jul 21
New minor risk - Shareholder dilution Jun 08
Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620). Jun 06
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023 May 20
Full year 2022 earnings released: EPS: ₩3,816 (vs ₩2,227 in FY 2021) Mar 10
Now 20% undervalued after recent price drop Feb 27
Price target decreased by 7.4% to ₩205,714 Feb 25
Investor sentiment deteriorates as stock falls 18% Feb 10
Daewoong Pharmaceutical Begins the First Administration of Bersiporocin Feb 06
Daewoong Pharmaceutical Co.,Ltd Submits NDA for Its Global New Drug Fexuclue in 11 Countries, Only 1 Year After Approval in Korea Jan 28
Consensus forecasts updated Jan 21
Upcoming dividend of ₩600 per share Dec 21
Daewoong Pharmaceutical Announces Success in Developing New Antidiabetic Medication Dec 07
Now 20% undervalued after recent price drop Nov 22
Less than half of directors are independent Nov 16
Daewoong Pharmaceutical Announces Phase 3 Clinical Trial Results of New Diabetes Treatment Enavogliflozin Nov 02
Investor sentiment improved over the past week Oct 27
Price target increased to ₩235,714 Sep 21
Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-In-Class Irreversible Oral Dual Acting Inhibitor for Autoimmune Diseases Aug 16
Price target increased to ₩235,000 Jul 31
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug Jul 21
Investor sentiment improved over the past week Jun 30
Less than half of directors are independent Apr 27
Daewoong Pharmaceutical Submits NDA for its Global New Drug Fexuclue Tablets to the Philippines Mar 29
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 13
Daewoong pharmaceutical Co.,Ltd Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy Feb 26
Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug Jan 26
Upcoming dividend of ₩600 per share Dec 22
Price target increased to ₩199,000 Jul 30
Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes Jun 02
Daewoong Pharmaceutical of South Korea Announces PRS-Inhibitor for Idiopathic Pulmonary Fibrosis Shows Promising Result in Early Stage Clinical Test May 28
First quarter 2021 earnings released: ₩2,139 loss per share (vs ₩65.00 profit in 1Q 2020) May 23
Price target increased to ₩147,143 May 09
Evolus, Inc. and Daewoong Pharmaceuticals Co., Ltd. Enter into Settlement Agreement Mar 25
Full year 2020 earnings released: EPS ₩1,196 (vs ₩2,132 in FY 2019) Mar 17
Daewoong pharmaceutical Co.,Ltd., Annual General Meeting, Mar 26, 2021 Mar 12
New 90-day low: ₩121,000 Mar 10
Price target raised to ₩126,625 Feb 25
New 90-day high: ₩119,000 Dec 07
Third quarter 2020 earnings released: EPS ₩223 Nov 20
Price target lowered to ₩110,000 Nov 18
New 90-day low: ₩91,900 Oct 26
Daewoong Pharmaceutical Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment Sep 30
Price target lowered to ₩123,214 Aug 02
Winst- en omzetgroeiprognoses KOSE:A069620 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (KRW Millions ) Datum Inkomsten Inkomsten Vrije kasstroom Geldmiddelen uit operationele activiteiten Gem. Aantal analisten 12/31/2026 1,521,022 126,868 129,886 177,583 5 12/31/2025 1,402,804 112,227 120,367 161,883 5 12/31/2024 1,300,481 74,554 78,156 129,200 5 6/30/2024 1,399,052 90,872 -130,838 84,726 N/A 3/31/2024 1,388,699 114,474 -53,452 126,812 N/A 12/31/2023 1,375,329 121,739 -19,618 136,009 N/A 9/30/2023 1,341,290 46,381 43,333 170,054 N/A 6/30/2023 1,332,284 51,305 19,019 136,131 N/A 3/31/2023 1,304,151 44,030 6,342 118,959 N/A 12/31/2022 1,280,092 42,240 6,162 118,215 N/A 9/30/2022 1,255,325 82,107 -13,414 87,701 N/A 6/30/2022 1,214,081 72,576 -65 78,402 N/A 3/31/2022 1,181,714 61,231 -25,785 65,359 N/A 12/31/2021 1,152,976 24,506 -34,727 39,994 N/A 9/30/2021 1,117,201 11,539 -21,549 45,667 N/A 6/30/2021 1,103,387 2,971 -8,568 68,925 N/A 3/31/2021 1,067,635 -11,030 20,341 81,301 N/A 12/31/2020 1,055,424 12,753 43,714 100,981 N/A 9/30/2020 1,075,831 -1,657 -2,683 53,237 N/A 6/30/2020 1,068,433 -2,480 2,987 49,749 N/A 3/31/2020 1,107,158 16,828 13,031 57,437 N/A 12/31/2019 1,113,426 22,006 8,989 57,600 N/A 9/30/2019 1,098,180 -8,021 81,272 126,212 N/A 6/30/2019 1,086,724 -6,314 33,847 97,101 N/A 3/31/2019 1,055,675 -12,079 2,178 66,602 N/A 12/31/2018 1,031,427 -15,152 -8,863 47,500 N/A 9/30/2018 995,896 19,610 -8,088 49,029 N/A 6/30/2018 990,152 25,296 -24,103 48,832 N/A 3/31/2018 973,800 31,077 N/A 82,155 N/A 12/31/2017 960,307 31,581 N/A 103,938 N/A 9/30/2017 959,672 39,318 N/A 60,986 N/A 6/30/2017 927,950 34,453 N/A 49,717 N/A 3/31/2017 898,632 27,433 N/A 21,664 N/A 12/31/2016 883,920 26,970 N/A 15,377 N/A 9/30/2016 862,689 19,704 N/A 19,176 N/A 6/30/2016 869,026 26,021 N/A 43,180 N/A 3/31/2016 857,252 34,413 N/A 44,974 N/A 12/31/2015 839,686 42,930 N/A 35,888 N/A 9/30/2015 812,337 44,657 N/A 21,960 N/A 6/30/2015 778,975 28,576 N/A 26,489 N/A 3/31/2015 758,475 30,555 N/A 36,310 N/A 12/31/2014 735,889 31,544 N/A 25,945 N/A 9/30/2014 734,716 31,176 N/A 42,933 N/A 6/30/2014 714,185 56,700 N/A 21,313 N/A 3/31/2014 690,275 58,808 N/A 24,093 N/A 12/31/2013 682,508 58,400 N/A 54,157 N/A
Meer tonen
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei A069620 ( 17.2% per jaar) ligt boven de spaarquote ( 2.7% ).
Winst versus markt: De winst van A069620 ( 17.2% per jaar) zal naar verwachting langzamer groeien dan de markt KR ( 29.3% per jaar).
Hoge groeiwinsten: De winst van A069620 zal naar verwachting groeien, maar niet aanzienlijk .
Omzet versus markt: De omzet van A069620 ( 4.4% per jaar) zal naar verwachting langzamer groeien dan de markt KR ( 10.1% per jaar).
Hoge groei-inkomsten: De omzet van A069620 ( 4.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen A069620 zal naar verwachting over 3 jaar laag zijn ( 12.3 %).
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
